Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAL_001
- Development stage
- Phase 2
- Lead developer
- Sichuan Yanyang Biotechnology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
KAL_001 is an innovative live biotherapeutic product (LBP) being developed by Sichuan Yanyang Biotechnology for the treatment of bacterial vaginosis (BV) and postmenopausal atrophic vaginitis (AV). As a microbiome-based therapy, KAL_001 is designed to restore the healthy vaginal microenvironment by introducing beneficial live bacteria. This approach aims to displace pathogenic species and alleviate symptoms associated with vaginal dysbiosis and mucosal atrophy by re-establishing a protective microbial balance. The drug is currently in the IND-enabling stage, with the developer preparing for regulatory submissions to initiate clinical trials.
- Brand names
- KAL-001KAL001KAL 001
- Other names
- KAL-001KAL001KAL 001
Beyond the preview
Go deeper on KAL_001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAL_001.